Stay updated on Pembrolizumab for Recurrent Glioblastoma Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab for Recurrent Glioblastoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab for Recurrent Glioblastoma Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    7 days ago
    No Change Detected
  3. Check
    14 days ago
    Change Detected
    Summary
    Site revision updated from v3.4.1 to v3.4.2; no changes to core study information or page layout are evident. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2026-02-13T12:27:50.000Z thumbnail image
  4. Check
    22 days ago
    Change Detected
    Summary
    Revision: v3.4.1 was added and v3.4.0 was removed from the page.
    Difference
    0.1%
    Check dated 2026-02-05T17:12:16.000Z thumbnail image
  5. Check
    44 days ago
    Change Detected
    Summary
    A new Revision: v3.3.4 is added and the previous Revision: v3.3.3 is removed.
    Difference
    0.1%
    Check dated 2026-01-15T04:48:55.000Z thumbnail image
  6. Check
    65 days ago
    Change Detected
    Summary
    A new Locations section appears with Texas as a site, replacing the earlier Texas Locations entry; the HHS Vulnerability Disclosure link is removed.
    Difference
    0.2%
    Check dated 2025-12-24T14:46:21.000Z thumbnail image
  7. Check
    94 days ago
    Change Detected
    Summary
    Publications section wording updated to replace 'the study results' with 'the results of the study' and to add a version tag (Revision: v3.3.2) while removing the older tag (v3.2.0). To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2025-11-25T14:51:44.000Z thumbnail image
  8. Check
    102 days ago
    Change Detected
    Summary
    The government funding and operating status notice has been removed from the page, while core study details, eligibility criteria, and contact information remain unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.4%
    Check dated 2025-11-18T07:30:01.000Z thumbnail image

Stay in the know with updates to Pembrolizumab for Recurrent Glioblastoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab for Recurrent Glioblastoma Clinical Trial page.